Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 19 studies | 32% ± 15% | |
oligodendrocyte | 15 studies | 49% ± 17% | |
astrocyte | 14 studies | 34% ± 14% | |
macrophage | 13 studies | 40% ± 18% | |
microglial cell | 12 studies | 42% ± 13% | |
GABAergic neuron | 10 studies | 42% ± 25% | |
oligodendrocyte precursor cell | 10 studies | 33% ± 14% | |
fibroblast | 10 studies | 31% ± 15% | |
glutamatergic neuron | 9 studies | 46% ± 26% | |
myeloid cell | 9 studies | 32% ± 12% | |
adipocyte | 9 studies | 29% ± 9% | |
retinal rod cell | 7 studies | 35% ± 14% | |
retinal cone cell | 7 studies | 52% ± 17% | |
dendritic cell | 7 studies | 33% ± 10% | |
interneuron | 6 studies | 46% ± 24% | |
smooth muscle cell | 6 studies | 23% ± 4% | |
neuron | 5 studies | 45% ± 21% | |
endothelial cell of lymphatic vessel | 5 studies | 28% ± 9% | |
monocyte | 5 studies | 52% ± 11% | |
pericyte | 5 studies | 25% ± 9% | |
type I pneumocyte | 5 studies | 28% ± 7% | |
type II pneumocyte | 5 studies | 36% ± 9% | |
classical monocyte | 4 studies | 21% ± 2% | |
non-classical monocyte | 4 studies | 20% ± 4% | |
granule cell | 4 studies | 27% ± 9% | |
cardiac muscle cell | 4 studies | 20% ± 3% | |
mast cell | 4 studies | 26% ± 7% | |
epithelial cell | 4 studies | 41% ± 22% | |
Mueller cell | 4 studies | 30% ± 14% | |
amacrine cell | 4 studies | 19% ± 5% | |
club cell | 4 studies | 26% ± 7% | |
conventional dendritic cell | 3 studies | 24% ± 7% | |
GABAergic interneuron | 3 studies | 36% ± 6% | |
mesothelial cell | 3 studies | 26% ± 4% | |
mononuclear phagocyte | 3 studies | 30% ± 10% | |
GABAergic amacrine cell | 3 studies | 23% ± 7% | |
glycinergic amacrine cell | 3 studies | 20% ± 3% | |
retinal ganglion cell | 3 studies | 32% ± 14% | |
hepatocyte | 3 studies | 49% ± 22% | |
retinal pigment epithelial cell | 3 studies | 51% ± 20% | |
connective tissue cell | 3 studies | 20% ± 4% | |
ependymal cell | 3 studies | 32% ± 13% | |
T cell | 3 studies | 22% ± 3% | |
alveolar macrophage | 3 studies | 52% ± 12% | |
ciliated cell | 3 studies | 25% ± 8% | |
erythrocyte | 3 studies | 57% ± 18% | |
lymphocyte | 3 studies | 27% ± 6% | |
basal cell | 3 studies | 39% ± 26% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2162.08 | 1443 / 1445 | 100% | 23.06 | 183 / 183 |
lung | 100% | 2731.37 | 577 / 578 | 100% | 18.84 | 1154 / 1155 |
breast | 100% | 1994.90 | 459 / 459 | 99% | 31.35 | 1112 / 1118 |
brain | 99% | 1987.03 | 2616 / 2642 | 100% | 24.69 | 705 / 705 |
thymus | 100% | 2007.12 | 652 / 653 | 99% | 16.79 | 598 / 605 |
ovary | 99% | 1366.87 | 179 / 180 | 99% | 11.97 | 425 / 430 |
kidney | 100% | 1453.81 | 89 / 89 | 98% | 16.39 | 882 / 901 |
uterus | 100% | 1529.36 | 170 / 170 | 98% | 14.62 | 449 / 459 |
skin | 100% | 3147.06 | 1808 / 1809 | 98% | 25.64 | 461 / 472 |
bladder | 100% | 1817.81 | 21 / 21 | 97% | 13.48 | 488 / 504 |
stomach | 99% | 1234.48 | 355 / 359 | 98% | 13.02 | 280 / 286 |
intestine | 100% | 1642.38 | 966 / 966 | 96% | 11.85 | 507 / 527 |
prostate | 100% | 1413.89 | 244 / 245 | 96% | 12.87 | 483 / 502 |
adrenal gland | 100% | 2421.88 | 258 / 258 | 93% | 12.69 | 215 / 230 |
liver | 100% | 1317.08 | 225 / 226 | 92% | 10.42 | 372 / 406 |
pancreas | 91% | 770.44 | 300 / 328 | 99% | 13.65 | 176 / 178 |
muscle | 100% | 3418.92 | 803 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5077.88 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 2084.21 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.26 | 1 / 1 |
blood vessel | 100% | 1946.56 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 2211.84 | 1203 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 14.78 | 44 / 45 |
eye | 0% | 0 | 0 / 0 | 94% | 15.40 | 75 / 80 |
heart | 90% | 1340.87 | 777 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 90% | 10.83 | 26 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1904263 | Biological process | positive regulation of TORC1 signaling |
GO_0006508 | Biological process | proteolysis |
GO_0016579 | Biological process | protein deubiquitination |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
Gene name | USP32 |
Protein name | Ubiquitin specific peptidase 32 Ubiquitin carboxyl-terminal hydrolase 32 (EC 3.4.19.12) (Deubiquitinating enzyme 32) (Renal carcinoma antigen NY-REN-60) (Ubiquitin thioesterase 32) (Ubiquitin-specific-processing protease 32) USP32 protein ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | USP10 |
Description | FUNCTION: Deubiquitinase that can remove conjugated ubiquitin from target proteins, such as RAB7A and LAMTOR1 . Acts as a positive regulator of the mTORC1 signaling by mediating deubiquitination of LAMTOR1, thereby promoting the association between LAMTOR1 and the lysosomal V-ATPase complex and subsequent activation of the mTORC1 complex . . |
Accessions | ENST00000589552.1 ENST00000593071.1 ENST00000588898.1 ENST00000590133.5 K7EPL4 ENST00000592339.5 ENST00000300896.9 [Q8NFA0-1] Q8NFA0 ENST00000591768.1 Q4VC15 ENST00000393003.7 [Q8NFA0-2] Q6IRT0 K7EKK3 K7EQL6 ENST00000590297.1 K7EN13 ENST00000589335.5 K7ENU6 K7EL53 K7EII4 K7EKZ1 |